Medley Therapeutics Advances First-in-Human Gene Therapy Trial for Heart Regeneration After Safety Milestone
核心洞察
Medley Therapeutics (搜索) completed dosing of the first three patients with YAP101 (搜索), marking the first clinical investigation of a genetic medicine designed to induce endogenous cardiac regeneration.
The Phase 1 SALVADOR-HF trial's independent Safety Review Team recommended dose escalation after favorable safety findings in patients with advanced ischemic heart failure.
YAP101 (搜索) uses an AAV vector to deliver shRNAs that transiently suppress Hippo signaling and activate YAP (搜索), enabling self-limiting myocardial regeneration through the heart's own repair mechanisms.
Medley Therapeutics (搜索) has achieved a significant milestone in cardiac regenerative medicine by successfully completing dosing of the first cohort in its Phase 1 SALVADOR-HF trial, marking the first clinical investigation of a genetic medicine designed to induce endogenous heart muscle regeneration. The company announced that following favorable safety findings in three patients with advanced ischemic heart failure, the study's independent Safety Review Team recommended escalation to the next protocol-defined dose level.
Breakthrough Gene Therapy Approach
YAP101 (搜索) represents a first-in-class adeno-associated virus (AAV) genetic medicine that targets the fundamental mechanisms of cardiac repair. The therapy uses a cardiomyocyte-specific promoter to express short hairpin RNAs (shRNAs), which transiently suppress Hippo signaling and activate YAP (搜索) with the goal of enabling self-limiting regeneration of heart muscle.
"Induction of endogenous regeneration of human heart muscle is the holy grail of modern medicine," said James F. Martin, MD, PhD, Founder of Medley Therapeutics (搜索) and Director of the Cardiomyocyte Renewal Laboratory at Baylor College of Medicine. "YAP101 (搜索) is designed to unlock the heart's own repair mechanism by transiently lifting the Hippo pathway 'brake' and activating YAP (搜索) via shRNAs delivered directly to cardiomyocytes."
The core technology for YAP101 (搜索) was developed in the Martin Laboratories at The Texas Heart Institute at Baylor College of Medicine, building on preclinical studies that successfully demonstrated cardiomyocyte regeneration.
Clinical Trial Design and Patient Population
The SALVADOR-HF trial is being conducted at The Texas Heart Institute at Baylor College of Medicine in Houston, targeting patients with advanced ischemic heart failure with reduced ejection fraction (HFrEF). The study follows a dose-escalation design with three planned dose levels in the initial phase, targeting enrollment of 9-18 subjects, followed by a dose-level expansion of up to six additional subjects.
"Until now, there has not been a way to regenerate human heart tissue," said Emerson Perin, MD, PhD, Medical Director of Medley Therapeutics (搜索) and Director of the Center for Clinical Research at The Texas Heart Institute. "YAP101 (搜索) offers new hope for patients with heart failure. Our aim is to enable the heart to repair itself and reverse heart failure through a brief cardiac catheterization procedure."
Addressing Critical Medical Need
The advancement comes at a crucial time for patients with heart failure, a condition affecting tens of millions of people globally. Current treatment options remain limited, particularly for patients with advanced disease who have exhausted conventional therapies.
"For the tens of millions of people living with heart failure, progress can't come soon enough," said Olav Bergheim, Founder, Chairman and Chief Executive Officer of Medley Therapeutics (搜索). "Completing the first cohort and advancing to the next dose level is a decisive milestone for SALVADOR-HF—and an important step toward a potentially transformative treatment option."
Company Background and Pipeline
Medley Therapeutics (搜索), formerly known as YAP (搜索) Therapeutics, pioneers the development of advanced biologics and genetic medicines to treat chronic and life-threatening diseases. Founded by Dr. James F. Martin, Olav Bergheim, and the late Dr. James Willerson, the company's portfolio extends beyond cardiac regeneration to include genetic medicines for treating cardiac arrhythmias and advanced biologics targeting oncology and fibrotic diseases.
The successful completion of the first cohort represents a critical proof-of-concept for regenerative gene therapy approaches in cardiovascular medicine, potentially opening new avenues for treating heart failure through endogenous tissue repair mechanisms rather than traditional pharmacological interventions.